Organon pays $50M to pick up rights to pair of Eli Lilly migraine meds in Europe

Organon, the women's health-focused spinoff of Merck, has picked up the rights to distribute and promote a pair of migraine medicines overseas.

Monday, Organon unveiled a marketing pact with Eli Lilly to take charge of Emgality and Rayvow in Europe.